Optimizing the adeno-associated Viral Vector System: a Brief Summary

• Mays LE , WilsonJM. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol. Ther.19(1), 16–27 (2011).
   PubMed Web of Science ®Google Scholar
• Sonntag F , SchmidtK, KleinschmidtJA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA107(22), 10220–10225 (2010).
   PubMed Web of Science ®Google Scholar
• Burova E , IoffeE. Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther.12(Suppl. 1), S5–S17 (2005).
   PubMed Web of Science ®Google Scholar
• Pulicherla N , AsokanA. Peptide affinity reagents for AAV capsid recognition and purification. Gene Ther. DOI :10.1038/gt.2011.46 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Mingozzi F , HighKA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet.12(5), 341–355 (2011).
   PubMed Web of Science ®Google Scholar
• Buning H , PeraboL, CoutelleO, Quadt-HummeS, HallekM. Recent developments in adeno-associated virus vector technology. J. Gene Med.10(7), 717–733 (2008).
   PubMed Web of Science ®Google Scholar
• Derda R , TangSK, LiSCet al. Diversity of phage-displayed libraries of peptides during panning and amplification. Molecules 16(2), 1776–1803 (2011).
   PubMed Web of Science ®Google Scholar
• Michelfelder S , KohlschutterJ, SkorupaAet al. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One 4(4), e5122 (2009).
   PubMed Web of Science ®Google Scholar
• Ying Y , MullerOJ, GoehringerCet al. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther. 17(8), 980–990 (2010).
   PubMed Web of Science ®Google Scholar
• Grimm D , LeeJS, WangLet al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol.82(12), 5887–5911 (2008).
   PubMed Web of Science ®Google Scholar
• Koerber JT , KlimczakR, JangJHet al. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol. Ther. 17(12), 2088–2095 (2009).
   PubMed Web of Science ®Google Scholar
• Gray SJ , BlakeBL, CriswellHEet al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18(3), 570–578 (2010).
   PubMed Web of Science ®Google Scholar
• Li W , ZhangL, JohnsonJSet al. Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol. Ther. 17(12), 2067–2077 (2009).
   PubMed Web of Science ®Google Scholar
• Zhong L , LiB, MahCSet al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl Acad. Sci. USA 105(22), 7827–7832 (2008).
   PubMed Web of Science ®Google Scholar
• Kern A , SchmidtK, LederCet al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77(20), 11072–11081 (2003).
   PubMed Web of Science ®Google Scholar
• Opie SR , WarringtonKH Jr, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol.77(12), 6995–7006 (2003).
   PubMed Web of Science ®Google Scholar
• Asokan A , HamraJB, GovindasamyL, Agbandje-McKennaM, SamulskiRJ. Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J. Virol.80(18), 8961–8969 (2006).
   PubMed Web of Science ®Google Scholar
• Gruh I , WunderlichS, WinklerMet al. Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. J. Gene Med. 10(1), 21–32 (2008).
   PubMed Web of Science ®Google Scholar
• Davidson BL , McCrayPB Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet.12(5), 329–40 (2011).
   PubMed Web of Science ®Google Scholar
• Geisler A , JungmannA, KurreckJet al. microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther. 18(2), 199–209 (2011).
   PubMed Web of Science ®Google Scholar
• Qiao C , YuanZ, LiJet al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther. 18(4), 403–410 (2011).
   PubMed Web of Science ®Google Scholar
• Maersch S , HuberA, BuningH, HallekM, PeraboL. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology397(1), 167–175 (2010).
   PubMed Web of Science ®Google Scholar
• Halbert CL , MetzgerMJ, LamSL, MillerAD. Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production. Gene Ther.18(4), 411–417 (2011).
   PubMed Web of Science ®Google Scholar
• Lu H , QuG, YangX, XuR, XiaoW. Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver. Hum. Gene Ther.22(5), 625–632 (2011).
   PubMed Web of Science ®Google Scholar

Website

• Gene therapy clinical trials worldwide www.wiley.com/legacy/wileychi/genmed/clinical
   Google Scholar